Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 582.21 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; magnesium stearate; crospovidone; pregelatinised maize starch; colloidal anhydrous silica; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - ciprol is indicated for the treatment of infections caused by susceptible organisms in the conditions listed: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 873.32 mg (equivalent: ciprofloxacin, qty 750 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; pregelatinised maize starch; crospovidone; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - ciprol is indicated for the treatment of infections caused by susceptible organisms in the conditions listed: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be preformed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated beforeresults of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-postitive aerobic bacteria. if anaerobic organisms are suspected as accompanying agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 832.5 mg (equivalent: ciprofloxacin, qty 750 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type a; purified talc; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - the treatment of infections caused by susceptible organisms in the conditions listed below: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram- positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 555 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; purified talc; maize starch; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - the treatment of infections caused by susceptible organisms in the conditions listed below: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram- positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 277.5 mg (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: maize starch; colloidal anhydrous silica; microcrystalline cellulose; purified talc; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - the treatment of infections caused by susceptible organisms in the conditions listed below: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram- positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; macrogol 4000; hypromellose; maize starch; sodium starch glycollate; magnesium stearate; titanium dioxide; purified talc - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; purified talc; hypromellose; macrogol 4000; titanium dioxide; maize starch; sodium starch glycollate; magnesium stearate - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; maize starch; purified talc; titanium dioxide; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; hypromellose; macrogol 4000 - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Malta - English - Medicines Authority

bayer public limited company - ciprofloxacin - tablet - ciprofloxacin 250 milligram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

bayer public limited company - ciprofloxacin - tablet - ciprofloxacin 500 milligram(s) - antibacterials for systemic use